| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Li,Zhi-Wen | Chairman | 64.26% | SINPHAR PHARMACEUTICAL CO., LTD. |
| Li,Yi-Da | Vice Chairman | 0.04% | |
| Zhu,Huai-Zu | Director | 64.26% | SINPHAR PHARMACEUTICAL CO., LTD. |
| Yang,Hui-Hua | Director | 0.41% | |
| Lin,Shi-Jia | Director | 0.00% | |
| Zhang,Jin-Jian | Director | 0.00% | |
| Li,Zhi-Heng | Independent Director | 0.00% | |
| Zhang,Fu-Xing | Independent Director | 0.00% | |
| Chen,Wen-Feng | Independent Director | 0.00% |
Change Company Name to SYNCORE BIOTECHNOLOGY CO., LTD.
2024/07/11
Change Company Name to XINGGUO NEW DRUG CO., LTD. (FORMER NAME: XINGGUO BIOTECHNOLOGY CO., LTD.)
2022/06/14
Change Capital to 1,500,000,000
2019/07/15
Change Capital to 1,000,000,000
2013/04/01
Change Company Name to SYNCORE BIOTECHNOLOGY CO., LTD.
2012/11/20
下載完整報告查看完整數據
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 5,386 | 23,337 | 20,196 |
| Operating cost | 2,104 | 10,450 | 19,675 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 3,282 | 12,887 | 521 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 3,282 | 12,887 | 521 |
| Operating expenses | 16,940 | 70,643 | 46,023 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -13,658 | -57,756 | -45,502 |
| Non-operating income and expenses | 1 | 3,473 | 7,330 |
| Net profit (loss) before tax | -13,657 | -54,283 | -38,172 |
| Income tax expense (benefits) | 0 | - | 0 |
| Net profit (loss) of ongoing business for the current period | -13,657 | -54,283 | -38,172 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -13,657 | -54,283 | -38,172 |
| Other comprehensive profit (loss), net | -1,177 | -8,165 | -2,984 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -14,834 | -62,448 | -41,156 |
| Net profit (loss) attributable to owners of parent company | -13,657 | -54,283 | -38,172 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | 0 | 0 |
| Comprehensive profit (loss) attributable to owners of parent company | -14,834 | -62,448 | -41,156 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | 0 | 0 | 0 |
| Basic earnings per share (yuan) | 0 | -1 | -1 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | -12,787 | -49,241 | -82,373 |
| Net cash inflows (outflows) from investing activities | -104 | -457 | -778 |
| Net cash inflow (outflow) from financing activities | -2,402 | -9,514 | 78,675 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 41 | 3 | 27 |
| Increase (decrease) in cash and cash equivalents in the current period | -15,252 | -59,209 | -4,449 |
| Beginning balance of cash and cash equivalents | 205,487 | 264,696 | 269,145 |
| Ending balance of cash and cash equivalents | 190,235 | 205,487 | 264,696 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 248,746 | 260,460 | 310,481 |
| Non-current asset | 55,555 | 57,341 | 67,881 |
| Total asset | 304,301 | 317,801 | 378,362 |
| Current liability | 24,447 | 22,122 | 21,226 |
| Non-current liability | 0 | 991 | 0 |
| Total liability | 24,447 | 23,113 | 21,226 |
| share capital | 351,645 | 351,645 | 351,645 |
| Equity - secruity token | - | - | - |
| capital reserve | 66,907 | 66,907 | 105,080 |
| retained earning | -67,940 | -54,283 | -38,173 |
| Other equity | -70,758 | -69,581 | -61,416 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 279,854 | 294,688 | 357,136 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 279,854 | 294,688 | 357,136 |
| Share capital awaiting retirement (unit: share) | - | - | - |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 7 | 8 | 10 |
